NO317151B1 - Pavisning av antistoffproduksjon - Google Patents

Pavisning av antistoffproduksjon Download PDF

Info

Publication number: NO317151B1
Authority: NO; Norway
Prior art keywords: antibodies; antibody; solid phase; sample; lymphocytes
Prior art date: 1995-02-21

Application number

NO19973823A

Other languages

English (en)

Norwegian (no)

Other versions

NO973823L (no

NO973823D0 (no

Inventor

Lars Reinhardt Haaheim

Original Assignee

Plasmacute As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-02-21

Filing date

1997-08-20

Publication date

2004-08-30

1997-08-20 Application filed by Plasmacute As filed Critical Plasmacute As

1997-08-20 Publication of NO973823D0 publication Critical patent/NO973823D0/no

1997-10-20 Publication of NO973823L publication Critical patent/NO973823L/no

2004-08-30 Publication of NO317151B1 publication Critical patent/NO317151B1/no

Links

230000016784 immunoglobulin production Effects 0.000 title claims abstract description 24
238000000034 method Methods 0.000 claims abstract description 107
239000000427 antigen Substances 0.000 claims abstract description 87
102000036639 antigens Human genes 0.000 claims abstract description 86
108091007433 antigens Proteins 0.000 claims abstract description 86
210000004698 lymphocyte Anatomy 0.000 claims abstract description 66
239000007790 solid phase Substances 0.000 claims abstract description 47
208000015181 infectious disease Diseases 0.000 claims abstract description 45
210000004369 blood Anatomy 0.000 claims abstract description 42
239000008280 blood Substances 0.000 claims abstract description 42
230000027455 binding Effects 0.000 claims abstract description 37
238000001514 detection method Methods 0.000 claims abstract description 27
229940123573 Protein synthesis inhibitor Drugs 0.000 claims abstract description 20
239000000007 protein synthesis inhibitor Substances 0.000 claims abstract description 20
230000004044 response Effects 0.000 claims abstract description 15
230000028327 secretion Effects 0.000 claims abstract description 10
238000002965 ELISA Methods 0.000 claims description 44
239000000758 substrate Substances 0.000 claims description 11
YPHMISFOHDHNIV-FSZOTQKASA-N cycloheximide Chemical group C1[C@@H](C)C[C@H](C)C(=O)[C@@H]1[C@H](O)CC1CC(=O)NC(=O)C1 YPHMISFOHDHNIV-FSZOTQKASA-N 0.000 claims description 10
238000003018 immunoassay Methods 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
229940121819 ATPase inhibitor Drugs 0.000 claims description 2
239000000362 adenosine triphosphatase inhibitor Substances 0.000 claims description 2
239000013642 negative control Substances 0.000 claims 1
238000000746 purification Methods 0.000 claims 1
241001529453 unidentified herpesvirus Species 0.000 claims 1
210000004027 cell Anatomy 0.000 description 53
238000003556 assay Methods 0.000 description 27
238000012360 testing method Methods 0.000 description 25
238000004458 analytical method Methods 0.000 description 24
239000002953 phosphate buffered saline Substances 0.000 description 22
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 21
238000011534 incubation Methods 0.000 description 18
241000700605 Viruses Species 0.000 description 15
210000002966 serum Anatomy 0.000 description 15
238000002835 absorbance Methods 0.000 description 13
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 12
239000000243 solution Substances 0.000 description 12
239000002609 medium Substances 0.000 description 11
238000003786 synthesis reaction Methods 0.000 description 11
241000701074 Human alphaherpesvirus 2 Species 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
238000002255 vaccination Methods 0.000 description 10
102000003992 Peroxidases Human genes 0.000 description 8
238000010790 dilution Methods 0.000 description 8
239000012895 dilution Substances 0.000 description 8
238000002474 experimental method Methods 0.000 description 8
108040007629 peroxidase activity proteins Proteins 0.000 description 8
238000000926 separation method Methods 0.000 description 8
208000024891 symptom Diseases 0.000 description 7
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
230000008901 benefit Effects 0.000 description 6
239000003153 chemical reaction reagent Substances 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
239000000463 material Substances 0.000 description 6
102000004169 proteins and genes Human genes 0.000 description 6
108090000623 proteins and genes Proteins 0.000 description 6
230000002269 spontaneous effect Effects 0.000 description 6
230000000638 stimulation Effects 0.000 description 6
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
239000000872 buffer Substances 0.000 description 5
230000028993 immune response Effects 0.000 description 5
230000002163 immunogen Effects 0.000 description 5
206010022000 influenza Diseases 0.000 description 5
230000035945 sensitivity Effects 0.000 description 5
230000000405 serological effect Effects 0.000 description 5
238000005406 washing Methods 0.000 description 5
229930182816 L-glutamine Natural products 0.000 description 4
229930182555 Penicillin Natural products 0.000 description 4
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
239000006285 cell suspension Substances 0.000 description 4
239000001963 growth medium Substances 0.000 description 4
239000012678 infectious agent Substances 0.000 description 4
229960003971 influenza vaccine Drugs 0.000 description 4
238000002955 isolation Methods 0.000 description 4
239000003446 ligand Substances 0.000 description 4
229940049954 penicillin Drugs 0.000 description 4
239000012071 phase Substances 0.000 description 4
YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 4
239000012089 stop solution Substances 0.000 description 4
HRDVWDQQYABHGH-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-N,N-dimethylaniline hydrochloride Chemical compound Cl.CN(C)c1ccc(cc1)-c1ccc(cc1)N(C)C HRDVWDQQYABHGH-UHFFFAOYSA-N 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
208000029433 Herpesviridae infectious disease Diseases 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
206010043376 Tetanus Diseases 0.000 description 3
210000000628 antibody-producing cell Anatomy 0.000 description 3
239000006143 cell culture medium Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
210000005259 peripheral blood Anatomy 0.000 description 3
239000011886 peripheral blood Substances 0.000 description 3
-1 sheets Substances 0.000 description 3
229960005322 streptomycin Drugs 0.000 description 3
229960000814 tetanus toxoid Drugs 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
108090001008 Avidin Proteins 0.000 description 2
241000283707 Capra Species 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
241000282414 Homo sapiens Species 0.000 description 2
241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
241000725303 Human immunodeficiency virus Species 0.000 description 2
241000371980 Influenza B virus (B/Shanghai/361/2002) Species 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
230000003622 anti-hsv Effects 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
239000011616 biotin Substances 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
208000035850 clinical syndrome Diseases 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
239000000562 conjugate Substances 0.000 description 2
238000012258 culturing Methods 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
230000014509 gene expression Effects 0.000 description 2
230000006054 immunological memory Effects 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
239000011148 porous material Substances 0.000 description 2
238000011002 quantification Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000009870 specific binding Effects 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
238000008157 ELISA kit Methods 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
108010001336 Horseradish Peroxidase Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
206010029719 Nonspecific reaction Diseases 0.000 description 1
101000820468 Pyrococcus horikoshii (strain ATCC 700860 / DSM 12428 / JCM 9974 / NBRC 100139 / OT-3) Membrane-bound protease PH1510 Proteins 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
108010090804 Streptavidin Proteins 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000004913 activation Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
239000010836 blood and blood product Substances 0.000 description 1
229940125691 blood product Drugs 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
230000037029 cross reaction Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
239000000499 gel Substances 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000003312 immunocapture Methods 0.000 description 1
230000000984 immunochemical effect Effects 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
208000037801 influenza A (H1N1) Diseases 0.000 description 1
229960003130 interferon gamma Drugs 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
238000002372 labelling Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000006249 magnetic particle Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000015654 memory Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000003836 peripheral circulation Effects 0.000 description 1
239000007981 phosphate-citrate buffer Substances 0.000 description 1
238000009372 pisciculture Methods 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
239000012898 sample dilution Substances 0.000 description 1
238000005070 sampling Methods 0.000 description 1
238000009589 serological test Methods 0.000 description 1
241000894007 species Species 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
201000010740 swine influenza Diseases 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229940031418 trivalent vaccine Drugs 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Virology (AREA)
Food Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Pathology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
Microbiology (AREA)
General Physics & Mathematics (AREA)
Tropical Medicine & Parasitology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Investigating Or Analysing Biological Materials (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Steroid Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

NO19973823A 1995-02-21 1997-08-20 Pavisning av antistoffproduksjon NO317151B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9503406.2A GB9503406D0 (en)	1995-02-21	1995-02-21	Detection of antibody production
PCT/GB1996/000392 WO1996026443A1 (en)	1995-02-21	1996-02-21	Detection of antibody production

Publications (3)

Publication Number	Publication Date
NO973823D0 NO973823D0 (no)	1997-08-20
NO973823L NO973823L (no)	1997-10-20
NO317151B1 true NO317151B1 (no)	2004-08-30

Family

ID=10769981

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19973823A NO317151B1 (no)	1995-02-21	1997-08-20	Pavisning av antistoffproduksjon

Country Status (21)

Country	Link
US (1)	US6080552A (de)
EP (1)	EP0811165B1 (de)
JP (1)	JP3472929B2 (de)
CN (1)	CN1098460C (de)
AT (1)	ATE188551T1 (de)
AU (1)	AU709591B2 (de)
CA (1)	CA2213083C (de)
CZ (1)	CZ289582B6 (de)
DE (1)	DE69606024T2 (de)
DK (1)	DK0811165T3 (de)
ES (1)	ES2140821T3 (de)
FI (1)	FI117911B (de)
GB (1)	GB9503406D0 (de)
GR (1)	GR3032740T3 (de)
HU (1)	HU225687B1 (de)
NO (1)	NO317151B1 (de)
NZ (1)	NZ301770A (de)
PL (1)	PL182061B1 (de)
PT (1)	PT811165E (de)
RU (1)	RU2197733C2 (de)
WO (1)	WO1996026443A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0955544A1 (de) *	1998-05-06	1999-11-10	Hölzel Diagnostika Handels GmbH	Verfahren zum Erfassen von Primärsignalen bei der Zellkommunikation von Zellen des Immunsystems
GB9913819D0 (en) *	1999-06-14	1999-08-11	Plasmacute As	Assay
GB0325483D0 (en) *	2003-10-31	2003-12-03	Plasmacute As	Assay
US20050240353A1 (en) *	2004-04-21	2005-10-27	Hoffmann Technologies Corporation	Reagents, devices and methods for proteomic analysis with applications including diagnostics, vaccines, quality control and research
JP4412732B2 (ja) *	2005-04-19	2010-02-10	独立行政法人国立高等専門学校機構	リンパ球を利用した抗体検査方法および病原体特定方法
DE102007052518A1 (de) *	2007-10-29	2009-04-30	Autoimmun Diagnostika Gmbh	Verfahren zur in vitro-Diagnose und/oder in vitro- Therapieverfolgung von Infektionen
CA2946817A1 (en)	2014-05-05	2015-11-12	Cembre S.P.A.	Machine for the application and / or removal of connecting fasteners for rails
RU2756764C1 (ru) *	2021-06-09	2021-10-05	Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр терапии и профилактической медицины" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ТПМ" Минздрава России)	Способ определения функциональной активности системы комплемента человека для прогноза тяжести течения системной воспалительной реакции

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5019497A (en) *	1984-11-09	1991-05-28	Lennart Olsson	Human squamous lung carcinoma cell specific antigens and antibodies
US4707443A (en) *	1985-04-19	1987-11-17	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Soluble interleukin-2 receptor as a disease indicator and a method of assaying the same
CA2011099A1 (en) *	1989-04-19	1990-10-19	Stephen C. Wardlaw	Determination of lymphocyte reactivity to specific antigens in blood
US5188942A (en) *	1990-10-09	1993-02-23	Consultants For Applied Biosciences, Inc.	Method for determining bluetongue virus antibodies in serum

1995
- 1995-02-21 GB GBGB9503406.2A patent/GB9503406D0/en active Pending
1996
- 1996-02-21 EP EP96903122A patent/EP0811165B1/de not_active Expired - Lifetime
- 1996-02-21 WO PCT/GB1996/000392 patent/WO1996026443A1/en active IP Right Grant
- 1996-02-21 RU RU97115554/13A patent/RU2197733C2/ru not_active IP Right Cessation
- 1996-02-21 CA CA002213083A patent/CA2213083C/en not_active Expired - Fee Related
- 1996-02-21 PT PT96903122T patent/PT811165E/pt unknown
- 1996-02-21 AU AU47268/96A patent/AU709591B2/en not_active Ceased
- 1996-02-21 DK DK96903122T patent/DK0811165T3/da active
- 1996-02-21 JP JP52549296A patent/JP3472929B2/ja not_active Expired - Fee Related
- 1996-02-21 DE DE69606024T patent/DE69606024T2/de not_active Expired - Lifetime
- 1996-02-21 ES ES96903122T patent/ES2140821T3/es not_active Expired - Lifetime
- 1996-02-21 AT AT96903122T patent/ATE188551T1/de not_active IP Right Cessation
- 1996-02-21 HU HU9801448A patent/HU225687B1/hu not_active IP Right Cessation
- 1996-02-21 CN CN96192047A patent/CN1098460C/zh not_active Expired - Fee Related
- 1996-02-21 NZ NZ301770A patent/NZ301770A/en not_active IP Right Cessation
- 1996-02-21 US US08/913,137 patent/US6080552A/en not_active Expired - Fee Related
- 1996-02-21 CZ CZ19972634A patent/CZ289582B6/cs not_active IP Right Cessation
1997
- 1997-08-14 PL PL96322209A patent/PL182061B1/pl not_active IP Right Cessation
- 1997-08-20 NO NO19973823A patent/NO317151B1/no not_active IP Right Cessation
- 1997-08-20 FI FI973418A patent/FI117911B/fi not_active IP Right Cessation
2000
- 2000-02-23 GR GR20000400440T patent/GR3032740T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
RU2197733C2 (ru)	2003-01-27
CN1098460C (zh)	2003-01-08
NO973823L (no)	1997-10-20
HU225687B1 (en)	2007-06-28
NZ301770A (en)	1999-04-29
EP0811165A1 (de)	1997-12-10
DE69606024T2 (de)	2000-09-14
EP0811165B1 (de)	2000-01-05
CN1176000A (zh)	1998-03-11
FI117911B (fi)	2007-04-13
CA2213083C (en)	2007-12-04
DE69606024D1 (de)	2000-02-10
FI973418A0 (fi)	1997-08-20
JPH11500226A (ja)	1999-01-06
NO973823D0 (no)	1997-08-20
HUP9801448A2 (hu)	1998-10-28
CZ289582B6 (cs)	2002-02-13
FI973418A (fi)	1997-08-20
DK0811165T3 (da)	2000-05-08
CZ263497A3 (cs)	1998-02-18
ES2140821T3 (es)	2000-03-01
GB9503406D0 (en)	1995-04-12
HUP9801448A3 (en)	2000-09-28
JP3472929B2 (ja)	2003-12-02
GR3032740T3 (en)	2000-06-30
PT811165E (pt)	2000-04-28
WO1996026443A1 (en)	1996-08-29
AU709591B2 (en)	1999-09-02
PL322209A1 (en)	1998-01-19
PL182061B1 (pl)	2001-10-31
AU4726896A (en)	1996-09-11
US6080552A (en)	2000-06-27
ATE188551T1 (de)	2000-01-15
CA2213083A1 (en)	1996-08-29

Publication	Publication Date	Title
EP0216191B1 (de)	1991-06-19	Immunologisches Testverfahren für HTLV-III-Antigene
US6916626B1 (en)	2005-07-12	Detection of Candida
Westblom et al.	1992	Diagnosis of Helicobacter pylori infection in adult and pediatric patients by using Pyloriset, a rapid latex agglutination test
JPH08503302A (ja)	1996-04-09	尿中における性行為感染症に関連する微生物に対する抗体のイムノアッセイ
WO2008108510A1 (en)	2008-09-12	Diagnostic kit for leptospirosis
NO317151B1 (no)	2004-08-30	Pavisning av antistoffproduksjon
US5641624A (en)	1997-06-24	Method for measuring anti-HIV-1 p24 antibody and use thereof
US20080206790A1 (en)	2008-08-28	Assay for determining the presence or amount of newly synthesized antibodies
US20100267009A1 (en)	2010-10-21	Method for the in vitro diagnosis and/or in vitro therapy monitoring of infections
US20070026386A1 (en)	2007-02-01	Method for the detection of newly acquired hiv infection
RU2726484C1 (ru)	2020-07-14	Способ диагностики риккетсиозов группы клещевой пятнистой лихорадки, иммуноферментная диагностическая тест-система для его осуществления
RU2695525C1 (ru)	2019-07-23	Способ иммуноферментного выявления возбудителя псевдотуберкулеза 1 серотипа на основе моноклональных антител к о-боковым цепям липополисахарида
EP0850418A1 (de)	1998-07-01	Verfahren zur diagnose einer bauchkrankheit
RU2275635C2 (ru)	2006-04-27	ПАНЕЛЬ СЫВОРОТОК С НОРМИРОВАННЫМ СОДЕРЖАНИЕМ АНТИТЕЛ КЛАССА IgG K АНТИГЕНАМ p17 И p41 TREPONEMA PALLIDUM И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
RU1780006C (ru)	1992-12-07	Способ диагностики туберкулеза
RU2156467C2 (ru)	2000-09-20	Иммуноферментная тест-система для выявления антител к возбудителю сифилиса
US20140087364A1 (en)	2014-03-27	Method and kit for determining the time of seroconversion of a patient infected with a virus
UA66096A (en)	2004-04-15	IMMUNOENZYME ASSAY KIT FOR DETECTING IgG AGAINST TOXOPLASMA GONDII IN HUMAN BLOOD SERUM (DIA-TOXO-IgG)
AU2003283116A1 (en)	2004-06-18	Method for the detection of newly acquired hiv infection
UA66567A (en)	2004-05-17	IMMUNOENZYME ASSAY KIT FOR QUANTIFYING IgG AGAINST RUBELLA VIRUS IN HUMAN BLOOD SERUM (DIA-RUBELLA-IgG)
UA66095A (en)	2004-04-15	IMMUNOENZYME ASSAY KIT FOR DETECTING IgG AGAINST HERPES VIRUSES TYPES I AND II IN HUMAN BLOOD SERUM (DIA-HSV 1/2-IgG)

Legal Events

Date	Code	Title	Description
2011-09-26	MM1K	Lapsed by not paying the annual fees